James Schoeneck has become CEO of Activx Biosciences (see story, p. 3), and former CEO and chief scientific officer John Kozarich has become president and chief R&D officer of the company. Schoeneck was previously president and CEO of Prometheus Laboratories. Prior to joining Prometheus, he was vice president and general manager of the immunology business unit of Centocor, a division of Johnson & Johnson.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.